How the New Oral GLP-1 Weight Loss Medications Work

GLP-1 Drugs Affect Your Gut and Brain
These medications also “enhance insulin secretion,” which can result in better blood sugar control and weight loss, says Sara Velayati, MD, an obesity medicine specialist at Montefiore Einstein’s Fleischer Institute Medical Weight Center in Bronx, New York. By acting on your brain, stomach, and blood sugar systems at the same time, GLP-1 medications can support meaningful weight loss and improve metabolic health over time, she says.
GLP-1s and Your Stomach: The Challenge
The peptide nature of this hormone is why developing effective oral versions of GLP-1 medications has been so challenging, says Dr. Velayati.
Oral Semaglutide
Because the gut is a challenging environment for absorption, oral semaglutide doses are much higher — 25 milligrams (mg) daily — than standard 2.4-mg weekly injections.
Even though the oral dose is higher, only a tiny fraction actually enters the bloodstream. Velayati says your body absorbs only about 0.4 to 1 percent of semaglutide taken by mouth. “So if you take 100 units, less than one actually reaches the bloodstream. But that tiny amount is still enough to have a meaningful clinical effect,” she says. The higher oral dose of semaglutide ensures enough medication survives the stomach acid.
Dosage Timing
If you’re thinking about trying the new weight loss pill instead of the weekly injection, you may need to rethink your morning routine. Unlike the injection, which can be given at any time, the pill requires a strict fasting window. You need to take it on an empty stomach with no more than 4 ounces (oz) of plain water, and wait at least 30 minutes before eating breakfast or drinking a cup of coffee.
“The SNAC matrix changes the pH locally where it hits the stomach lining, and this allows absorption,” says W. Timothy Garvey, MD, professor of medicine and director of The University of Alabama at Birmingham’s Diabetes Research Center. “Food prevents this interaction.”
If you eat too soon after taking the pill, food surrounds it in your stomach. That keeps the medication from touching your stomach lining the way it needs to in order to work, says Velayati. Similarly, drinking too much water can dilute the SNAC buffer, and the medication will simply be digested and wasted.
Small-Molecule Drugs
Peptide medications have a large molecular weight and mimic your body’s delicate regulatory signals. “Small molecules are chemically synthesized and designed to interact with receptors and enzymes,” says Dr. Garvey. “They’re smaller in molecular weight than peptide medications that mimic or interfere with endogenous bioregulatory peptides.”
Think of it this way: While a peptide is like a fragile piece of paper that dissolves in the rain, a small molecule is like a tiny pebble, sturdy enough to survive the digestive storm.
Velayati says these newer drugs are “even more exciting,” because their natural stability allows them to survive stomach acid without a special chemical enhancer (like SNAC). Since your body doesn’t try to “digest” these molecules, these drugs likely won’t require strict fasting or perfect timing. In other words, you may eventually be able to take these medications alongside your morning protein latte.
The Takeaway
- Oral GLP-1 medications work by mimicking a natural hormone that regulates appetite, slows digestion, and increases insulin secretion to support weight loss and metabolic health.
- The first FDA-approved pill, oral semaglutide, uses a chemical enhancer called SNAC to protect the medication from stomach acid. It requires significantly higher doses than injections to be effective.
- To ensure proper absorption, people taking oral semaglutide must follow a strict fasting routine. ?You take the pill with minimal water and wait 30 minutes before eating or drinking.
- Future “small-molecule” drugs currently in development are chemically sturdier than peptides like semaglutide. This may eventually get rid of the need for strict fasting requirements and special chemical enhancers in these drugs.
Resources We Trust
- Mayo Clinic: Pros and Cons of GLP-1 Agonists for Weight Loss
- American Journal of Managed Care: FDA Approves Oral Semaglutide as First GLP-1 Pill for Weight Loss
- Harvard Health Publishing: How Does Ozempic Work? Understanding GLP-1s for Diabetes, Weight Loss, and Beyond
- Cleveland Clinic: GLP-1 Agonists
- Obesity Medicine Association: Top Weight Loss Medications
- GLP-1 Agonists. Cleveland Clinic. July 3, 2023.
- Hayashi D et al. What Is Food Noise? A Conceptual Model of Food Cue Reactivity. Nutrients. November 17, 2023.
- Collins L et al. Glucagon-Like Peptide-1 Receptor Agonists. StatPearls. February 29, 2024.
- FDA Approves Novo Nordisk's Wegovy Pill, the First and Only Oral GLP-1 for Weight Loss in Adults. PR Newsire. December 22, 2025.
- What Is SNAC in Oral Semaglutide? Biopharma PEG. September 7, 2023.
- Wharton S et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. New England Journal of Medicine. September 16, 2025.

Sean Hashmi, MD
Medical Reviewer
Sean Hashmi, MD, is an experienced nephrologist and obesity medicine specialist based in Southern California. As the regional director for clinical nutrition and weight management at a prominent healthcare organization in Southern California, Dr. Hashmi oversees the development and implementation of cutting-edge nutritional programs and weight management strategies. With his innovative approach and unwavering commitment to providing evidence-based solutions, he is a highly sought-after speaker and a leader in his field.
Hashmi founded the nonprofit organization SelfPrinciple.org to provide accessible and accurate health, nutrition, and wellness information to the public. Through this platform, he shares the latest research findings, empowering individuals to make informed decisions about their well-being. Self Principle also supports children's education by providing scholarships, books, and supplies, so that students have the resources necessary to succeed academically and build a brighter future.

Susan Jara
Author
Susan Jara is a health communications strategist and writer with more than 15 years of experience transforming complex medical information into clear, accurate, and engaging content for diverse audiences of patients and caregivers. She specializes in patient education, health literacy, and SEO-driven content strategy, with expertise across chronic disease, mental health, addiction, arthritis, autoimmune conditions, and wellness.
Susan holds a bachelor’s degree in journalism and media studies from New York University’s Gallatin School of Individualized Study. Her career includes leadership roles at the Global Healthy Living Foundation and Health Monitor Network, where she developed multichannel health content across web, email, podcasts, video, social media, and print. Susan's work reaches millions of readers each year, and she collaborates with leading healthcare providers, researchers, advocacy groups, and industry partners to create resources that reach millions of readers each year.